#1 Clinical Trials Search in Europe

Rasburicase

Rasburicase is a medication being studied in various clinical trials for its effectiveness in treating hyperuricemia (high uric acid levels in the blood) and tumor lysis syndrome, a condition that can occur during cancer treatment. These trials are exploring how rasburicase works in different patient populations, including those with leukemia, lymphoma, and other cancers, as well as in patients with conditions like gout and metabolic syndrome. The studies aim to determine the optimal dosing, efficacy, and safety of rasburicase in managing uric acid levels and preventing complications associated with cancer treatment.

Table of Contents

What is Rasburicase?

Rasburicase is a medication used primarily in the treatment of high uric acid levels in the blood, a condition known as hyperuricemia. It’s also known by its brand names Elitek™ and Fasturtec®[1][2]. Rasburicase is a type of drug called a uricolytic agent, which means it helps break down uric acid in the body[3].

What Conditions Does Rasburicase Treat?

Rasburicase is primarily used to treat or prevent a serious condition called Tumor Lysis Syndrome (TLS). TLS occurs when cancer cells break down quickly, often at the start of chemotherapy, releasing their contents into the bloodstream. This can lead to high levels of uric acid, potassium, and phosphorus in the blood, which can cause kidney failure and other serious complications[4].

Rasburicase is used in patients with various types of cancer, including:

  • Leukemia (cancer of the blood cells)
  • Lymphoma (cancer of the lymphatic system)
  • Other hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes)[1][4]

In addition to its use in cancer patients, rasburicase is also being studied for its potential benefits in treating:

  • Chronic gout (a form of arthritis caused by high uric acid levels)[5]
  • Metabolic syndrome (a group of conditions that increase the risk of heart disease, stroke, and diabetes)[6]

How Does Rasburicase Work?

Rasburicase works by converting uric acid into a substance called allantoin. Unlike uric acid, allantoin is much more soluble in water, which means it can be easily eliminated from the body through urine. This helps to rapidly reduce uric acid levels in the blood, preventing the complications associated with hyperuricemia and TLS[4].

How is Rasburicase Administered?

Rasburicase is typically given as an intravenous (IV) infusion, which means it’s delivered directly into a vein. The dosage and duration of treatment can vary depending on the specific condition being treated and the patient’s individual needs. Some common administration methods include:

  • A single dose followed by additional doses as needed[7]
  • Daily doses for 3-5 consecutive days[2][4]
  • Doses given at specific intervals (e.g., weeks 1, 4, and 8) in some chronic conditions[5]

Effectiveness of Rasburicase

Rasburicase has been shown to be highly effective in rapidly reducing uric acid levels in patients at risk for TLS. Clinical trials have demonstrated that:

  • Most patients achieve normal uric acid levels within 24-48 hours of receiving rasburicase[8]
  • Rasburicase is more effective than traditional treatments like allopurinol in quickly lowering uric acid levels[1]
  • The medication can help prevent kidney damage and other complications associated with TLS[7]

Safety and Side Effects

While rasburicase is generally well-tolerated, like all medications, it can cause side effects. The most common side effects include:

  • Nausea and vomiting
  • Fever
  • Headache
  • Skin rashes[2]

In rare cases, rasburicase can cause serious allergic reactions. Patients with a history of asthma or severe allergies may be at higher risk for these reactions[9]. It’s important to inform your healthcare provider about any allergies or medical conditions you have before receiving rasburicase.

Rasburicase in Special Populations

Rasburicase is used in both adult and pediatric patients. However, its use may require special consideration in certain groups:

  • Children and adolescents: Rasburicase is approved for use in pediatric patients with leukemia, lymphoma, and solid tumors who are receiving anti-cancer therapy[10]
  • Patients with asthma or allergies: These patients may require closer monitoring due to the potential risk of allergic reactions[9]
  • Obese patients: Some studies are investigating the effects of rasburicase on insulin sensitivity and oxidative stress in obese individuals[6]

Ongoing Research and Future Directions

Researchers continue to study rasburicase to optimize its use and explore its potential in treating other conditions. Some areas of ongoing research include:

  • Determining the most effective dosing strategies to balance efficacy and cost-effectiveness[7]
  • Investigating the use of rasburicase in chronic conditions like gout[5]
  • Exploring the potential effects of rasburicase on insulin sensitivity and oxidative stress in metabolic disorders[6]

As research continues, our understanding of rasburicase and its potential applications may expand, potentially offering new treatment options for patients with various conditions related to high uric acid levels.

Aspect Details
Primary Uses Treatment of hyperuricemia, prevention and management of tumor lysis syndrome
Patient Populations Patients with hematologic malignancies, those at risk of tumor lysis syndrome, individuals with gout or metabolic syndrome
Dosing Regimens Typically 0.15-0.20 mg/kg IV daily for 3-7 days; some trials exploring single low doses
Efficacy Measures Reduction in uric acid levels, prevention of tumor lysis syndrome complications, improvement in gout symptoms
Safety Monitoring Allergic reactions, changes in blood tests, rare serious reactions like hemolysis in G6PD deficient patients
Combination Therapies Some trials combining rasburicase with allopurinol or other urate-lowering therapies
Special Populations Studies in pediatric patients, adults with asthma/allergies, obese individuals

FAQ

  • What is rasburicase used for in clinical trials? Rasburicase is primarily being studied for treating hyperuricemia (high uric acid levels) and preventing or managing tumor lysis syndrome, a complication that can occur during cancer treatment. It's being tested in patients with various cancers, including leukemia and lymphoma, as well as in conditions like gout and metabolic syndrome.
  • How does rasburicase work? Rasburicase is a urate oxidase enzyme that breaks down uric acid in the body. It helps to rapidly reduce high levels of uric acid in the blood, which can be beneficial in preventing complications during cancer treatment or in managing conditions like gout.
  • What are the typical doses of rasburicase used in clinical trials? Doses vary across trials, but common regimens include 0.15-0.20 mg/kg given intravenously once daily for 3-7 days. Some trials are also exploring single low doses (e.g., 1.5 mg or 3 mg) followed by other medications like allopurinol.
  • Are there any side effects associated with rasburicase in clinical trials? While rasburicase is generally well-tolerated, clinical trials are monitoring for potential side effects. These may include allergic reactions, especially in patients with a history of asthma or allergies. Other possible side effects being studied include changes in blood tests and rare but serious reactions like hemolysis in patients with G6PD deficiency.
  • Who is typically eligible for rasburicase clinical trials? Eligibility varies by trial, but common participants include patients with hematologic malignancies (blood cancers), those at risk of tumor lysis syndrome, individuals with hyperuricemia, and in some cases, patients with conditions like gout or metabolic syndrome. Some trials focus on specific age groups, such as children and adolescents or adults.

Ongoing Clinical Trials on Rasburicase

  • Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Portugal Spain

  • Testing rasburicase for preventing and treating kidney problems in adult patients with sepsis and high uric acid levels

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Germany

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Spain

  • Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Bulgaria Croatia Denmark Estonia France +5

Glossary

  • Hyperuricemia: A condition characterized by high levels of uric acid in the blood, which can lead to complications like gout or kidney problems.
  • Tumor Lysis Syndrome (TLS): A potentially life-threatening complication that can occur during cancer treatment, especially in patients with rapidly growing tumors. It happens when a large number of cancer cells die quickly, releasing their contents into the bloodstream.
  • Uric Acid: A waste product created when the body breaks down substances called purines. High levels of uric acid can lead to various health issues.
  • Rasburicase: A medication that works as a urate oxidase enzyme, helping to break down uric acid in the body. It's used to treat or prevent high uric acid levels, particularly in cancer patients.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Allopurinol: A medication used to lower uric acid levels in the blood, often used in combination with rasburicase in some clinical trials.
  • Gout: A form of arthritis caused by the buildup of uric acid crystals in joints, leading to inflammation and pain.
  • Hematologic Malignancies: Cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia and lymphoma.
  • Tophus: A deposit of uric acid crystals that can form under the skin in people with chronic gout.

References

  1. https://clinicaltrials.gov/study/NCT01564277
  2. https://clinicaltrials.gov/study/NCT04349306
  3. https://clinicaltrials.gov/study/NCT00651911
  4. https://clinicaltrials.gov/study/NCT00360438
  5. https://clinicaltrials.gov/study/NCT05312268
  6. https://clinicaltrials.gov/study/NCT01931527
  7. https://clinicaltrials.gov/study/NCT00628628
  8. https://clinicaltrials.gov/study/NCT00302653
  9. https://clinicaltrials.gov/study/NCT00186940
  10. https://clinicaltrials.gov/study/NCT00563771